جست‌وجوی استاد و پژوهشگر

• Molecular Biology
• Cell Biology
• MicroRNA Signaling
• +۵ مورد دیگر

Kyriaki Bakirtzis is an Adjunct Lecturer in Biology with a Ph.D. in Medicine from Boston University (2010), an M.Sc. in Immunology/Cancer Biology from Brunel University of London (2000), and a B.Sc. in Biology from Royal Holloway University of London (1999). Her research spans molecular mechanisms in inflammatory bowel disease (IBD), colon cancer, and neurogastroenterology, focusing on exosome-mediated miRNA signaling, neurotensin pathways, and hypoxia-related angiogenesis. She has led NIH-funded projects on miR-21 in colonic inflammation and HIF-1α-miR-210 signaling in colitis. Her work also explores cerebellar glucose transport and lipid metabolism. Education: Ph.D., Medicine, Boston University (2010) M.Sc., Immunology/Cancer Biology, Brunel University of London (2000) B.Sc., Biology, Royal Holloway University of London (1999) Her research projects include collaborations with NIH and CCFA, and she has presented at major conferences like Digestive Disease Week (DDW), receiving awards for her keynote speeches and Poster of Distinction. Kyriaki has contributed to understanding neurotensin and substance P signaling in intestinal inflammation and cancer, with publications in journals such as Am J Physiol Gastrointest Liver Physiol , Nature Microbiology , and The Journal of Biological Chemistry . Scientific Awards: Keynote Speaker, Digestive Disease Week (2017, 2011) Junior Faculty Award, Day of Medical Research (2014) Research Fellowship Award, CCFA (2011) She has also developed protocols for pre-adipocyte isolation and primary neuron cultures, with a focus on Glut4 vesicle function in the central nervous system. Her current roles include Scientific Director at ELPEN Pharmaceutical Co. and Academic Program Coordinator for the Panhellenic Association of Pharmaceutical Industry.

Andrew David Pattersonمشاهده پروفایل

استاد

• Microbiome
• Metabolomics
• Gut Microbiota
• +۵ مورد دیگر

Andrew David Patterson is a Professor of Biochemistry & Molecular Biology at Pennsylvania State University, with appointments in the Department of Veterinary and Biomedical Sciences, the Huck Institutes of the Life Sciences, the Penn State Cancer Institute, the One Health Microbiome Center, and the Center for Cannabis and Natural Product Pharmaceuticals (CCNPP). His research focuses on the complex interactions between host metabolism and the gut microbiome. Dr. Patterson's research interests span several interconnected areas related to host-microbiome interactions: Gut Microbiota and its role in health and disease Metabolomics approaches to understanding host-microbiome crosstalk Bile acid metabolism and signaling Aryl hydrocarbon receptor biology Environmental chemical impacts on host-microbiome interactions Non-alcoholic fatty liver disease mechanisms His recent publications demonstrate a strong focus on the gut microbiome's role in health and disease, with particular attention to how dietary components, environmental chemicals, and host metabolism interact. His work combines advanced metabolomics techniques with microbiome analysis to uncover novel mechanisms of host-microbiome communication, particularly in relation to bile acids, nuclear receptors, and environmental exposures. Dr. Patterson has received significant research funding from multiple NIH institutes, including the National Institute of Environmental Health Sciences, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Cancer Institute. His current projects examine environmental chemical impacts on host-microbiome interactions (2023-2026), FXR and gut microbiome modulation of non-alcoholic fatty liver disease (2019-2024), and an integrative analysis of metabolic phenotypes training program (2020-2025). With over 230 publications and an h-index of 70, Dr. Patterson has established himself as a leader in the field of host-microbiome-metabolome interactions. His work bridges basic science with potential clinical applications in metabolic and inflammatory diseases, contributing to multiple United Nations Sustainable Development Goals related to health and well-being.

• Microbiome
• Gut Microbiota
• Intestinal Flora
• +۵ مورد دیگر

Jordan Bisanz serves as an Assistant Professor in the Department of Biochemistry & Molecular Biology at Penn State, with affiliations to the Penn State Cancer Institute, One Health Microbiome Center, and the Cancer Institute's Mechanisms of Carcinogenesis program. His research bridges microbiology, cancer biology, and nutritional science, focusing on the complex interactions between host physiology and microbial communities. Dr. Bisanz's primary research interests center on the human gut microbiome, with particular emphasis on gut microbiota composition, microbial diversity, host-microbe interactions, and diet-microbe relationships. His work spans multiple disciplines including microbiology , oncology , nutrition , and systems biology , with applications to human health and disease prevention. His research fingerprint prominently features Intestine Flora (100%), Microbiome (96%), Gut Microbiome (91%), and Microflora (78%), demonstrating his specialization in gastrointestinal microbial ecosystems. His recent publications reveal a strong focus on how microbial communities influence human health outcomes, particularly in the contexts of cancer development, metabolic disorders, and infectious diseases. The research demonstrates sophisticated methodological approaches including synthetic microbiota construction, single-cell analysis, and comprehensive biomonitoring studies across diverse populations. His work shows consistent growth in output, with 55 total research outputs and significant engagement from the scientific community as evidenced by citations and media coverage. Dr. Bisanz currently leads three major research projects totaling over $2.5 million in funding, including the active NIH-funded project 'Decoding Microbial Diversity in the Human Gut Microbiome' (2023-2026) and two completed projects on diet-microbe interactions modulating host energy balance. His research has attracted attention from 14 news outlets, been blogged about, and shared across multiple social media platforms, indicating significant impact beyond academia. His laboratory work appears to focus on advanced microbiome analysis techniques, with recent publications describing single-cell atlases of microbial communities and investigations into how dietary components like black raspberry and pistachios modulate gut microbiota. This research has important translational applications for understanding and treating conditions ranging from Clostridioides difficile infection to cancer and metabolic disorders.

• Histology
• Embryology
• Veterinary Science
• +۵ مورد دیگر

Assistant Professor Şükran YEDİEL ARAS is a faculty member at Kafkas University's Faculty of Health Sciences, Department of Midwifery since 2018. She holds a Doctorate in Veterinary Histology and Embryology from Kafkas University's Institute of Health Sciences (2016), a Master's degree in the same field (2009), and a Bachelor's degree in Nursing from Yüzüncü Yıl University (2004). Doctorate: Veterinary Histology and Embryology (2009-2016), Kafkas University Master's: Veterinary Histology and Embryology (2005-2009), Kafkas University Bachelor's: Nursing Program (2000-2004), Yüzüncü Yıl University Dr. Yediel Aras specializes in histology, embryology, and veterinary science with particular focus on diabetes research and plant extract pharmacology. Her research primarily investigates the effects of various plant extracts (cinnamon, dandelion, nettle, ginger) on diabetic rat tissues, nerve growth factors, and inflammatory markers. She employs immunohistochemical methods to examine tissue responses to different treatments. Her publication record shows a clear progression toward increasingly complex studies involving multiple plant extracts and their combined effects on various organ systems. Recent work has expanded to include human tissue analysis, particularly in obstetrics and reproductive medicine contexts. She has published extensively in veterinary and medical journals, with a significant portion appearing in SCI-indexed publications. Poster first prize award (2023) Dr. Yediel Aras has successfully supervised three Master's students whose research focuses on midwifery education, infertility treatments, and pain management during childbirth. She has secured multiple research grants, serving as principal investigator on several projects examining plant extracts' effects on diabetic complications and inflammatory conditions. Her collaborative network spans 39 researchers, with particularly strong partnerships with Ebru Karadağ Sarı (31 collaborations) and Buket Bakır (10 collaborations). She maintains an active research laboratory focused on histological and immunohistochemical techniques, working with both animal models and human tissue samples. Her team regularly investigates oxidative stress markers, inflammatory cytokines, and molecular pathways affected by natural compounds.

• Lipid Metabolism
• Atherosclerosis
• Mouse Models
• +۵ مورد دیگر

Nicolette Huijkman is a researcher at the Department of Genetics within the University Medical Center Groningen at the University of Groningen. Her research focuses on lipid metabolism, atherosclerosis, and genetic metabolic disorders using mouse models to investigate LDL receptor biology and lipoprotein metabolism. She actively contributes to the understanding of cardiovascular and metabolic diseases through molecular and cellular approaches. Her primary research interests include Lipid Metabolism, Atherosclerosis, Mouse Models, LDL Receptor Biology, Genetic Metabolic Disorders, and Lipoprotein Metabolism as evidenced by her substantial research fingerprint. Her work demonstrates expertise in investigating how lipid transport mechanisms affect cardiovascular health and metabolic disorders. Analysis of her recent publications reveals a strong focus on the molecular mechanisms underlying lipid metabolism disorders. Her research spans from fundamental cellular processes like receptor recycling and lipoprotein assembly to clinical applications in personalized medicine for metabolic disorders. A notable trend is her integration of mouse models with clinical data to bridge basic science and patient care, particularly in disorders of lipid metabolism and fatty acid oxidation. Nicolette Huijkman's collaborative research network spans multiple institutions as evidenced by her co-authorship on numerous high-impact publications. Her work contributes to Sustainable Development Goals related to good health and well-being through advancing understanding of metabolic and cardiovascular diseases.

• Cell Biology
• Cancer Research
• DNA Replication
• +۴ مورد دیگر

Bart Westendorp is an Associate Professor and Department Chair (2023-2027) at Utrecht University's Faculty of Veterinary Medicine, Department of Biomolecular Health Sciences. His primary affiliation is with the Cell Biology, Metabolism & Cancer research group, and he maintains a dual appointment at the Hubrecht Institute (Uppsalalaan 8, Room 5.15). His work focuses on understanding cancer therapy resistance mechanisms at the single-cell level. His research expertise centers on cancer cell heterogeneity, DNA replication dynamics, and therapy resistance mechanisms. Using advanced methodologies including single-cell sequencing, live-cell imaging, and flow cytometry, his lab investigates how cancer cells adapt to treatments, particularly in muscle-invasive bladder cancer. Key research themes include E2F transcription factors, cell cycle regulation, replication stress tolerance, and carcinogenesis pathways. Analysis of his recent publications reveals strong trends in single-cell analysis of therapy resistance, with emphasis on FOXM1-mediated replication stress responses, cell cycle braking mechanisms, and kinase remodeling in disease contexts. His work bridges fundamental cell biology with translational cancer research, frequently employing multi-omics approaches to uncover heterogeneity in tumor responses. Professional activities include frequent invited talks on replication stress modeling (2023-2024) and single-cell analysis of bladder cancer drug resistance (2022). His media engagement includes significant coverage of his 2020 research on unstoppable cell cycles in cancer therapy resistance, widely disseminated through academic platforms and social media. His academic journey spans from Biomedical Sciences training at Utrecht University (1996-2001), PhD in Clinical Pharmacology at Groningen (2001-2005), postdoctoral work at Ottawa Heart Institute (2005-2008), to progressive roles at Utrecht University: Postdoctoral Researcher (2008-2012), Researcher (2014-2016), and University Lecturer/Assistant Professor (2016-present), culminating in his current Associate Professorship and Department Chair position.

Wilfried Ellmeierمشاهده پروفایل

استاد

• Immunology
• T Cell Biology
• Epigenetic Regulation
• +۸ مورد دیگر

Wilfried Ellmeier is a Professor of Immunobiology and Head of the Institute of Immunology at the Medical University of Vienna. He is a Corresponding Member of the Austrian Academy of Sciences (Division of Mathematics and Natural Sciences) since 2012, with a focus on epigenetic and transcriptional mechanisms governing T cell development, function, and T cell-mediated immunity. His work bridges immunology, molecular biology, and translational medicine, particularly in autoimmune diseases and lymphomagenesis. Education: Biochemistry (Diploma, University of Vienna, 1990), Molecular Pathology (PhD, University of Vienna/IMP, 1994), Postdoctoral studies (Skirball Institute/NYU Medical Center, 1995–1999) His research centers on histone deacetylases (HDACs) as key regulators of T cell immunity in health and disease, including autoimmune conditions like rheumatoid arthritis and intestinal inflammation. His lab employs multi-color flow cytometry, mouse genetics, next-gen sequencing, and immunometabolic approaches to dissect these mechanisms. Recent publications highlight HDAC1 as a therapeutic target in arthritis, immunomodulatory effects of bile acids like 24-Nor-ursodeoxycholic acid, epigenetic control of Treg/Th17 differentiation, and metabolic reprogramming of CAR T cells. These reflect his contributions to immunometabolism and precision therapy. Scientific Awards: START-Preis (FWF), Novartis-Preis für Biologie, APART Stipendium, Förderungspreis der Stadt Wien, Habilitation Prize from VFWF Ellmeier leads the FWF-funded SFB-F70 ‘HIT’ program (since 2019) and chairs the Austrian Society for Allergology and Immunology (ÖGAI, 2023–2024). His lab homepage at ellmeierlab.org details collaborative projects in T cell biology and European biomedical policy.

Isaac Ming-Cheng Chiuمشاهده پروفایل

استاد

• Neuroimmunology
• Pain Mechanisms
• Host Defense
• +۵ مورد دیگر

Isaac Ming-Cheng Chiu is a Professor of Immunology at Harvard Medical School, where he leads groundbreaking research at the intersection of neuroscience and immunology. His work investigates bidirectional neuro-immune interactions in pain, host defense, and tissue immunity through mechanistic studies in skin, gut, and central nervous system models. Education : A.B. in Biochemistry (Harvard College, 2002), Ph.D. in Immunology (Harvard Medical School, 2009) Postdoctoral Training : Molecular and Cell Biology (Harvard University) and Neurobiology (Boston Children’s Hospital, FM Kirby Center) His research has uncovered novel mechanisms of bacterial pathogen-brain communication, neuropeptide signaling in mucosal immunity, and gasdermin-mediated neurodegeneration. Key contributions include defining sensory neuron-immune cell synapses and discovering direct microbial activation of nociceptors. Major Scientific Awards : NIH Director’s New Innovator Award Burroughs Wellcome Fund Investigators in Pathogenesis Award Chan-Zuckerberg Initiative Ben Barres Early Career Award His publications across Cell , Nature , and Science demonstrate leadership in neurogastroenterology and neuroinflammatory disease research. Current projects focus on microbiota-brain-immune circuits and novel therapeutic targets for chronic pain and neurodegenerative disorders.

• Mucosal Immunology
• Inflammatory Bowel Disease
• Crohn's Disease
• +۹ مورد دیگر

Atul Bhan, MD, is a Professor of Pathology at Harvard Medical School and a Pathologist at Massachusetts General Hospital. He holds board certifications in Immunopathology and Pathology-Anatomic from the American Board of Pathology. His clinical expertise includes Autopsy Pathology and Immunopathology, with a focus on adult patients. Dr. Bhan completed his medical education at All India Institute of Medical Sciences (MD) and Christian Medical College & Hospital (MBBS), followed by residencies at Boston Children's Hospital and Boston Medical Center. Dr. Bhan's research focuses on Mucosal Immunology and Inflammatory Bowel Disease (IBD), particularly Crohn's disease and ulcerative colitis. His laboratory investigates: Regulatory B cells and their role in suppressing intestinal inflammation via IL-10 Th-1 and Th-17 immune pathways in IBD pathogenesis Autophagy mechanisms (e.g., ATG16L1 variant) in antibacterial defense Intestinal alkaline phosphatase as a therapeutic for metabolic disorders Gut homing receptor α4β7 integrin (leading to Vedolizumab/Entyvio® development) Dr. Bhan serves as Associate Director of the Center for the Study of Inflammatory Bowel Disease at MGH and collaborates extensively with researchers studying mucosal immunity, macrophage function, and metabolic regulation. His work has received over $19 million in annual research funding, supporting 20,000 sq.ft. of laboratory space at MGH. Publications demonstrate research spanning mucosal immunity (45%), inflammatory bowel disease mechanisms (30%), liver pathology (15%), and cancer immunology (10%). Recent work emphasizes genetic risk factors (C1orf106, GPR65), immune cell regulation (SLAMF4, IL-10R), and diagnostic innovations (shear-wave elastography). Dr. Bhan directs the Bhan Laboratory at MGH, which employs experimental models including TCR alpha knockout mice to study chronic intestinal inflammation. Key collaborators include Dr. Cox Terhorst (immune receptors), Dr. Ramnik Xavier (autophagy), Dr. Scott Snapper (IL-10 signaling), and Dr. Richard Hodin (intestinal alkaline phosphatase).

• Pediatric Gastroenterology
• Intestinal Organoids
• Gut-Brain Axis
• +۷ مورد دیگر

James Bayrer, MD, PhD is a Professor of Pediatrics in the School of Medicine at the University of California, San Francisco (UCSF), specializing in pediatric gastroenterology and physician-scientist research. His work focuses on the intestinal epithelium as the body's largest environmentally exposed surface and sensory endocrine organ. Education: M.D. from Case Western Reserve University School of Medicine (2007) Ph.D. in Pharmacology from Case Western Reserve University (2005) Dr. Bayrer's research program investigates how the intestine senses and responds to environmental stimuli through molecular pathways, with particular focus on enteroendocrine cells as gut chemosensors. His laboratory utilizes human intestinal organoids and animal models to study intestinal wound healing, visceral pain syndromes, and the gut-brain axis. This work has significant implications for understanding and treating pediatric inflammatory bowel disease and related conditions. Analysis of his publication record shows consistent thematic development from his early work on nuclear receptors to current research on LRH-1's role in intestinal homeostasis, enteroendocrine cell development, and gut-spinal cord connections. His research spans neurogastroenterology, molecular biology, and translational medicine with strong emphasis on pediatric applications. Major Scientific Awards: National Academy of Sciences 2024 Kavli Fellow Society for Pediatric Research 2024 New Member Outstanding Science Award Mayo Clinic 2024 Kelsey Family Named Professor Lectureship Society for Pediatric Research 2023 Elected Member American Gastroenterological Association Early Career Investigator Award (2018) Dr. Bayrer serves as Principal Investigator on multiple NIH-funded research projects totaling over $2 million in active funding, including an R01 grant running through 2026 on LRH-1 activity in gut regeneration. His mentoring includes guidance for junior investigators through the RAP Pilot Award program focused on pediatric IBD organoid research. The Bayrer Lab at UCSF employs cutting-edge approaches including intestinal organoid biorepositories, genetic disease models, and molecular technologies to investigate epithelial renewal mechanisms and sensory gut epithelium function, with direct applications to developing new treatments for children with gastrointestinal disorders.

• Viral Pathogenesis
• HIV Research
• Hepatitis Virus Research
• +۷ مورد دیگر

Melanie Ott, MD, PhD is a Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine. Her research focuses on the molecular mechanisms of viral pathogenesis, with particular emphasis on HIV-1, Hepatitis B and C Viruses (HBV and HCV), Zika virus, and SARS-CoV-2. She has established four main research technologies: rapid quantitative tests, human organoids, a viral protein library, and transcriptomics and chromatin biology. Dr. Ott's laboratory has made significant contributions to understanding viral-host interactions, particularly during the COVID-19 pandemic where her team applied their expertise to develop new diagnostic tools and identify shared host factors for coronaviruses. Her research spans both basic virology and translational applications, with numerous NIH-funded projects investigating HIV latency, viral replication mechanisms, and therapeutic interventions. Her recent publications demonstrate a strong focus on SARS-CoV-2 variants, viral protein structures, host-pathogen interactions, and innovative approaches to viral diagnostics and therapeutics. The research shows a clear trend toward understanding conserved viral mechanisms across different pathogens to identify panviral therapeutic targets. Her work increasingly integrates advanced technologies including organoid models, structural biology, and high-throughput screening approaches. Dr. Ott serves as Principal Investigator on multiple NIH grants, including projects on HIV obstruction by programmed epigenetics, modeling intestinal dysfunction in HIV infection with organoid technology, and harnessing RNA-binding properties for HIV-1 self-testing. Her laboratory has developed important models for studying viral infections in human-relevant systems, particularly using organoid technology to investigate host responses. Her work with human airway organoids has provided critical insights into SARS-CoV-2 infection mechanisms and host responses, while her HIV research continues to explore epigenetic mechanisms of viral latency. The laboratory's research bridges fundamental virology with translational applications, with implications for both pandemic preparedness and chronic viral disease management.

• Cardiovascular Sciences
• Pharmacology
• Nanodrug Delivery
• +۳ مورد دیگر

Srinivas Tipparaju serves as Professor and Chair of Pharmaceutical Sciences at the University of South Florida's Taneja College of Pharmacy, located at the Tampa campus (12901 Bruce B. Downs Blvd). His educational background includes a BPharm from Nagpur College of Pharmacy (1996), MPharm from BITS Pilani (1998), PhD in Pharmacology from Jamia Hamdard/CDRI (2002), and postdoctoral training in Cardiovascular Research at Emory University (2003). His research integrates cardiovascular pharmacology , ion channel regulation , and nanodrug delivery systems . Primary interests include: Metabolic modulation of potassium channels (Kvβ subunits) Nanoparticle-based glucocorticoid delivery for muscle injury Cardioprotective drug development for diabetic complications Redox signaling in cardiac electrophysiology Recent publications (2016-2025) demonstrate consistent focus on: Nanoparticle therapeutics characterization and optimization Cardiac ion channel pathophysiology in metabolic diseases Translational applications of electrophysiology research Clinical pharmacology of diabetes and statin therapies Awards and honors include: FCVS (American Physiological Society, 2019) Best Researcher Award (USF, 2014) AHA Scientist Development Grant (2008) Fellowships from AHA (2003) and USF leadership programs Professional memberships include the American Physiological Society (2013-present) and American Heart Association (2003-present). No explicit information about grants, laboratories, or student advising is provided in the source material.

Carmen Fasoمشاهده پروفایل

استاد

• Unconventional Protein Secretion
• Parasitology
• Cell Biology
• +۵ مورد دیگر

Carmen Faso is a Professor at the Institute of Cell Biology, University of Bern, and serves as a Multidisciplinary Center for Infectious Diseases (MCID) Interfaculty Lecturer and Group Leader. Her research focuses on unconventional protein secretion (UPS) and membrane trafficking in parasitic protists, particularly Giardia lamblia and Entamoeba histolytica. She leads a multidisciplinary team involving molecular parasitology, mucosal immunology, and biomedical engineering to develop translational approaches for parasite-host interactions. Current projects include organoid-based co-cultivation systems and microfluidics platforms for studying intestinal infections. Her recent publications highlight advancements in understanding UPS mechanisms, endocytic compartments, and phosphoinositide signaling in Giardia lamblia. These works span molecular biology, cell biology, and evolutionary biology, with applications in parasitology and drug development. Scientific awards and funding sources include grants from the Swiss National Science Foundation (SNSF) and the Ruth and Artur Scherbarth Foundation. Collaborations extend to institutions like the University of Zurich, BNITM Hamburg, BIOCEV Prague, and Uppsala University. Her laboratory includes PhD students Dawid Warmus, Jonas Luginbühl, and Mathi Funk, and former lab members such as Dr. Shweta V. Pipaliya, Dr. Zahra Rezaei, and Tim Schärer. The group also collaborates with technical staff like Dr. Corina Wirdnam.

• Cancer Stem Cells
• Nanomedicine
• Tissue Engineering
• +۳ مورد دیگر

Juan Antonio Marchal Corrales serves as a Researcher within the Department of Human Anatomy and Embryology at the University of Granada's Faculty of Health Sciences, maintaining an active academic profile since 2001 with significant contributions through 2025. His institutional affiliation anchors his work in anatomical sciences while extending into translational biomedical research. He earned his Doctorate from the University of Granada in 1996 with a thesis on induced differentiation therapy using novel antineoplastic agents in muscle lineage cells, supervised by Dr. Antonia Aránega Jiménez. This foundational work established his trajectory in cancer mechanisms and therapeutic development. Dr. Marchal Corrales' research centers on cancer stem cell targeting and biomaterial-based therapeutic delivery systems. His laboratory investigates nanomedicine approaches for tumor-specific drug delivery, bioink development for tissue regeneration, and molecular mechanisms of cancer progression. Key methodologies include CRISPR editing, exosome engineering, and 3D bioprinting of tumor microenvironments, with emphasis on pancreatic, breast, and colorectal cancers. Analysis of his 2022-2025 publications reveals a strategic pivot toward clinically translatable solutions: nanoparticle drug carriers, bioactive wound-healing matrices, and engineered immunotherapies dominate his output. Over 70% of recent work focuses on overcoming treatment resistance through cancer stem cell targeting, demonstrating consistent innovation in nanocarrier design and tumor microenvironment modulation. His collaborative network spans oncology, biomaterials science, and regenerative medicine research groups across Europe, though specific grant details remain unreported in source materials. Current projects likely involve handheld bioprinting devices and transactivator-free CAR-T cell platforms based on his latest publications. Within the Department of Human Anatomy and Embryology, he contributes to anatomical education while leading a research team focused on cancer microenvironment modeling. His dual expertise in anatomical sciences and translational oncology enables unique approaches to tissue-engineered cancer models and regenerative therapies.

• MicroRNA Biomarkers
• Cancer Genomics
• Molecular Oncology
• +۶ مورد دیگر

Robin Mjelle is a Research Fellow at the Department of Clinical and Molecular Medicine , Norwegian University of Science and Technology (NTNU) . Their work bridges molecular oncology, immunology, and bioinformatics, with a focus on microRNA biomarkers in cancers and metabolic diseases. University: Norwegian University of Science and Technology (NTNU) Department: Department of Clinical and Molecular Medicine Academic Rank: Research Fellow Research Interests: MicroRNA profiling for early cancer detection and prognosis Toll-like receptor signaling in hematologic malignancies Epigenetic regulation in metabolic and autoimmune diseases Longitudinal transcriptomics analysis tools Host-microbiota interaction profiling Scientific Contributions: Developed sMETASeq pipeline for combined microbiota and host RNA analysis (2020) Created TiSA time-series analysis tool for transcriptomics (2023) Identified miR-105-5p as survival predictor in multiple myeloma (2022) Discovered miR-320 association with lung cancer progression (2022) Elucidated IL-32's role in myeloma cell metabolism (2021)